Is ZLCS a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

2,643 people get ZLCS articles and Market Currents by email alert.

Get email alerts on ZLCS »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Zalicus Awaiting Data On Potential New Pain Medication
Len Zehr • Thu, May 23 • 16 Comments
Watching Zalicus Like A Hawk
PropThink • Thu, May 2 • 41 Comments
Zalicus: Renewing Partnership With Novartis Will Be Vital For 2013 Revenues
Heather Ingrassia • Wed, Apr 3 • 19 Comments
Why Zalicus' Stock Intrigues
PropThink • Thu, Mar 7 • 19 Comments
Meeting With Zalicus Management Confirms Z160 Potential; Big Pharma Awaiting Trial Data
PropThink • Tue, Jan 22 • 21 Comments
The Future Of Zalicus In 2013
James Stocklasar Thomas Jr. • Tue, Jan 15 • 39 Comments
Will 2013 Be A Better Year For Zalicus?
C.R. Jackson • Thu, Jan 10 • 2 Comments
Zalicus: Bears And Bulls
Jorge Aura • Mon, Nov 26, 2012 • 29 Comments
A Bare Bones Valuation On Zalicus: Over 40% Upside Potential
Jason Napodano • Wed, Oct 10, 2012 • 41 Comments
Prednisporin: A Well-Kept Secret
Jorge Aura • Fri, Sep 14, 2012 • 13 Comments
Zalicus Has Sufficient Funds Until 2014
Jorge Aura • Tue, Sep 11, 2012 • 24 Comments
Zalicus To Discontinue Development Of Synavive - What Now?
Icarus Falling • Mon, Sep 10, 2012 • 23 Comments
Zalicus Misses Key Secondary Endpoint
James Stocklasar Thomas Jr. • Mon, Sep 10, 2012 • 30 Comments
Zalicus: Pain Free Investing
Icarus Falling • Fri, Sep 7, 2012 • 37 Comments
Buy Zalicus For A 120% Upside
Jorge Aura • Wed, Sep 5, 2012 • 65 Comments
Zalicus: When Push Comes To Shove
James Stocklasar Thomas Jr. • Fri, Aug 31, 2012 • 77 Comments
Zalicus: Ready To Rebound
Efsinvestment • Fri, Aug 31, 2012 • 13 Comments
Early Thursday: Make Money On Zalicus, Why Not?
James Stocklasar Thomas Jr. • Thu, Aug 30, 2012 • 23 Comments
Going Into Monday Zalicus' S-3 Surprise
James Stocklasar Thomas Jr. • Mon, Aug 27, 2012 • 30 Comments
Zalicus: Preparing For A Q3 Catalyst
Longwood Bulls • Fri, Aug 17, 2012 • 15 Comments

To learn more about Seeking Alpha Pro, click here.

2 Biotechs Primed For Prosperity In 2013
MacsJV • Thu, May 2 • 18 Comments
AcelRx Pharmaceutical's Potential Billion-Dollar Treatment Under The Radar
Scott Matusow • Tue, Mar 19 • 20 Comments
A Study Of 3 Biotechs - A Story Of Hope, Potential And Partnerships
Craig Keolanui • Mon, Mar 18 • 2 Comments
Speculative Biotech Stocks That Could Bounce 50% On Upcoming Catalysts
BuySellShort • Thu, Feb 21 • 10 Comments
8 Biotech Growth Names: Greg Wade
Life Sciences Report • Fri, Feb 8 • 3 Comments
Meetings With Management: JPM Healthcare And The Biotech Showcase
PropThink • Fri, Jan 11 • 19 Comments
Looking Beyond The JPM Global Healthcare Conference: More Biotech Than Meets The Eye
Nouvelle Asset Management • Tue, Jan 8 • 14 Comments
2 Biotech Companies Making Considerable Strides When It Comes To Pain Management
Matt Schilling • Thu, Jan 3 • 6 Comments
Weekly Biotech Recap: Anticipation, Divergence
Brian L. Wilson • Mon, Dec 17, 2012 • 6 Comments
Top 5 Fiscal Cliff Biotech Buys
James Stocklasar Thomas Jr. • Wed, Dec 5, 2012 • 10 Comments
3 Small-Cap Biopharmas With Trade Catalysts And Speculation Investment Potential
Scott Matusow • Tue, Dec 4, 2012 • 21 Comments
Teva: What Would Be The Best Acquisition Candidate?
Jorge Aura • Wed, Nov 28, 2012 • 15 Comments
Smart Day Traders Ring The Register On Acadia And Zalicus
James Stocklasar Thomas Jr. • Wed, Nov 28, 2012 • 15 Comments
Why Cash Overrules The Momentary Market Bounce
James Stocklasar Thomas Jr. • Tue, Nov 27, 2012 • 14 Comments
Why I'm 'In Cash' For Biotechs In A Bearish Market
James Stocklasar Thomas Jr. • Wed, Nov 21, 2012 • 37 Comments
Why Does Sanofi Want To Sublicense Prednisporin?
Jorge Aura • Wed, Oct 31, 2012 • 5 Comments
3 Small-Cap Healthcare Companies That Have Bottomed Out In October
Jorge Aura • Mon, Oct 15, 2012 • 14 Comments
Reconsidering Zalicus And Antares In Light Of Shakeups
James Stocklasar Thomas Jr. • Wed, Oct 3, 2012 • 18 Comments
Zogenix: Upcoming Catalysts Should Provide Upside
Scott Matusow • Tue, Oct 2, 2012 • 26 Comments
Tracking Recent Buy Calls And Investments By The Maxim Group
Scott Matusow • Fri, Sep 28, 2012 • 31 Comments

CombinatoRx, Inc. Q4 2009 Earnings Call Transcript
Thu, Mar 25, 2010
CombinatoRx, Inc. Q2 2009 Earnings Call Transcript
Mon, Aug 10, 2009
CombinatoRx, Inc., Q4 2008 Earnings Call Transcript
Wed, Mar 4, 2009
CombinatoRx, Inc. Q4 2007 Earnings Call Transcript
Wed, Mar 19, 2008

Zalicus Advancing Clinical Development of Z944, Its Novel, Oral, T-Type Calcium Channel Blocker, for the Treatment of Pain

Business Wire (Jun 4, 2013)
Zalicus to Present at the Jefferies 2013 Global Healthcare Conference

Business Wire (May 29, 2013)
Zalicus Presents Data on Novel, Oral, N- and T-Type Calcium Channel Blockers for the Treatment of Pain

Business Wire (May 10, 2013)
Zalicus Secures New $25 Million Funding Commitment from Lincoln Park Capital

Business Wire (May 8, 2013)
Zalicus Reports Financial Results for the First Quarter 2013

Business Wire (May 2, 2013)
Zalicus Granted Key Formulation Patent for Z160

Business Wire (Apr 2, 2013)
Zalicus Presents Data Demonstrating Advantages of State-Dependent Ion Channel Screening

Business Wire (Mar 19, 2013)
Zalicus Reports Financial Results for the Fourth Quarter and Year End 2012

Business Wire (Mar 6, 2013)
Zalicus Granted Composition-of-Matter Patent for Z944

Business Wire (Feb 20, 2013)
Zalicus to Present at the 2013 BIO CEO & Investor Conference

Business Wire (Feb 5, 2013)
Zalicus Initiates the Second of Two Phase 2a Studies with Z160

Business Wire (Jan 3, 2013)
Zalicus to Present at the Oppenheimer 23rd Annual Healthcare Conference

Business Wire (Dec 5, 2012)
Zalicus’ Z160 for Chronic Neuropathic Pain Selected as a Top 10 Project to Watch

Business Wire (Nov 27, 2012)
Zalicus Reports Financial Results for the Third Quarter 2012

Business Wire (Nov 8, 2012)
Zalicus Licensee, Sanofi, Provides Status Update on Prednisporin (FOV1101)

Business Wire (Oct 25, 2012)
Zalicus Reports Top Line Phase 2b Trial Results with Synavive in Rheumatoid Arthritis

Business Wire (Sep 10, 2012)
Zalicus Initiates the First of Two Phase 2a Studies with Z160, a First-in-Class, Oral, State-Dependent, Selective N-type Calcium Channel Blocker, for the Treatment of Chronic Neuropathic Pain

Business Wire (Sep 4, 2012)
Hertz Global Holdings, Zalicus Among Stocks Gapping Up Monday

at Fox Business (Aug 27, 2012)
Zalicus Announces FDA Approval of 32mg Dose Strength of EXALGO®

Business Wire (Aug 27, 2012)
Zalicus to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference

Business Wire (Aug 8, 2012)

ZLCS vs. ETF Alternatives

Company Description

We are a biopharmaceutical company pioneering the field of synergistic combination pharmaceuticals. Going beyond traditional combinations, we use our innovative drug discovery technology to create product candidates with novel multi-target mechanisms of action striking at the biological... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 2, 10:56 AM Zalicus (ZLCS): Q1 EPS of -$0.06 beats by $0.01. Revenue of $3.7M beats by $0.26M. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
Tuesday, April 2, 8:59 AM The Patent Office grants Zalicus (ZLCS +7.6%) a patent that covers a range of compositions for, and methods of using, its Z160 drug for treating pain. The decision protects Z160 until 2032. The medicine is in two Phase IIa trials for chronic neuropathic pain. (PR) 2 Comments [Healthcare, On the Move]
Tuesday, March 19, 9:10 AM Zalicus (ZLCS +8.15%) presents preclinical data showing the advantages of applying the firm's "state dependent screening approach" in identifying novel calcium channel blockers for the treatment of pain. One such blocker, Z160, is in Phase IIa trials. It's designed for treating chronic neuropathic pain. (PR) 2 Comments [Healthcare, On the Move]
Wednesday, March 6, 1:48 PM Zalicus (ZLCS -0.5%) trades slightly lower today despite a solid Q4 earnings beat. Revenue for the quarter came in at $3.8M, up from $2.6M a year earlier. Oppenheimer reiterated its Outperform rating and $2.00 price target on the shares, saying the two ongoing Z160 Phase IIa proof-of-concept studies in chronic neuropathic pain are expected to yield encouraging top-line data by late-2H13. 4 Comments [Healthcare, Earnings]
Wednesday, March 6, 7:41 AM Zalicus (ZLCS): Q4 EPS of -$0.06 beats by $0.02. Revenue of $3.79M beats by $0.6M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, January 4, 2:59 PM Zalicus (ZLCS) continues its upward trajectory from yesterday, gaining another 3% on the back yesterday's +15% run after saying it's initiated the second of two Phase 2a clinical studies with Z160, its treatment for chronic neuropathic pain. Comment! [Healthcare, On the Move]
Thursday, January 3, 11:41 AM Zalicus (ZLCS +9.5%) trades up today after saying it's initiated the second of two Phase 2a clinical studies with Z160, a selective N-type calcium channel blocker designed to potentially treat chronic neuropathic pain. Comment! [Healthcare, On the Move]
Monday, September 10, 2012, 9:10 AM Premarket gainers: KSW +22%. CTIC +5%.
Losers: GERN -47%. ZLCS -46%. TITN -16%. Comment! [On the Move]
Monday, September 10, 2012, 8:09 AM Following a Phase 2b trial, Zalicus (ZLCS) says "in the absence of a clinically meaningful benefit with Synavive compared to its active glucocorticoid component, Zalicus will discontinue further clinical development with Synavive. These results are not only disappointing to Zalicus, but also to the many steroid-dependent patients who are seeking a safer treatment alternative." (PR) 1 Comment [Breaking News, Healthcare]
Monday, August 27, 2012, 12:03 PM Zalicus (ZLCS +11.1%) takes off after announcing the FDA has approved the sale of 32mg tablets for Covidien's (COV +0.6%) Exalgo pain-relief drug. The sale of 8, 12, and 16mg tablets was approved in 2010. Zalicus receives royalties on Exalgo sakes. (PR) 2 Comments [Healthcare, On the Move]
Monday, August 27, 2012, 9:10 AM Premarket gainers: KNXA +41%. ZLCS +23%. HTZ +16%. HCBK +14%. IMGN +13%. NOK +9%. SRPT +8%. DTG +7%. NAV +7%. MTSL +7%. TIF +6%. RIMM +5%. CAR +5%.
Losers: IDIX -17%. VRNG -6%. PPHM -6%. 1 Comment [On the Move]
Thursday, August 9, 2012, 9:10 AM Premarket gainers: RBN +27%. RDEN +17%. MDRX +17%. JRCC +11%. PSTI +7%. PHMD +7%. ZLCS +6%. AEG +6%. NOK +6%. EAT +5%.
Losers: MATR -9%. MNST -7%. QCOR -7%. 1 Comment [On the Move]
Tuesday, August 7, 2012, 9:49 AM More on Zalicus (ZLCS +6.25%) Q2: company has again extended its partnership with Novartis (NVS), "validating the value" of Zalicus' cHTS technology for developing cancer treatments. Zalicus is also on track to start Phase 2a trials of Z160, a drug for neuropathic pain, and to report results of a Phase IIb trial for Synavive, which is used for rheumatoid arthritis. (PR) Comment! [On the Move, Healthcare]
Tuesday, August 7, 2012, 9:17 AM Zalicus (ZLCS): Q2 EPS of -$0.09 beats by $0.02. Revenue of $2.9M (+58% Y/Y) beats by $0.3M. Shares +8.9% premarket. (PR) Comment! [Healthcare, On the Move]
Tuesday, August 7, 2012, 9:10 AM Premarket gainers: USHS +37%. BSFT +24%. FOSL +21%. LOPE +18%. BVSN +10%. ZLCS +10%. VRNG +9%. IHG +8%. CIM +6%. NOK +6%. MGM +5%. DCTH +5%.
Losers: WMS -20%. LEAP -18%. NIHD -16%. ELN -11%. CORT -10%. HEK -9%. DUF -8%. Comment! [On the Move]
Tuesday, July 31, 2012, 9:39 AM Zalicus (ZLCS +6.6%) shoots higher at the open after a glowing writeup from blogger Ramsay Schrum. ZLCS' Z160 & Z944 calcium channel blockers have the potential to create the first pain management drug that is orally administered without the abuse and addictive side effects that come with the use of opioids, Schrum writes. Comment! [Healthcare, Quick Ideas, On the Move]

Gare17
Check out my article : http://seekingalpha.com/p/137f5 $NVS $MRK $PFE $ZLCS
May 6, 1:08 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Gare17
If we don't hear from $ZLCS next Monday or Tuesday with Novartis renewal I think buyout rumors will start .. $NVS $MRK $PFE #Ions
Apr 26, 12:43 PM
Reply (1)

• !Report Abuse
View all 1 replies
Gare17: $ZLCS buyout or spinoff with $NVS for Chts technology
Apr 29, 4:17 PM
• !Report Abuse
Add a reply...

140 characters

Coaly1234
$ZLCS - next steps investors to vote on reverse split. If Novartis joint venture comes about in May would be good.
Apr 23, 6:53 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Coaly1234
$ZLCS - K8 filed stock revesal on the way (1 to 10 reverse split possible) Hopefully that will carry $ZLCS through to a testing of Z160
Apr 22, 1:14 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

cjvincenti
$ZLCS
Mar 11, 5:39 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Coaly1234
2012 Full Year Report was positve and should allow $ZLCS to easily travel through 2014. Now if Z160 and Z944 hit, price goes UP
Mar 6, 7:58 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

mr.lynch
great long term play, $ZLCS
Mar 2, 5:23 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Coaly1234
$ZLCS The SEC filings were to define severence benefits for 2 execs, and to report the sale of 112K shares by the Pres - No Buyout Rumors.
Jan 30, 5:46 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Gare17
$ZLCS SEC Filings posted on company website ... buyout rumors starting
Jan 10, 4:08 AM
Reply (2)

• !Report Abuse
View all 2 replies
mr.lynch: STILL FOLLOWING $ZLCS ? IM LONG ON IT
Mar 2, 5:25 PM
• !Report Abuse
Gare17: yep long as well .. i think May - August we'll see some significant progress .. Im expecting data in September for LSR study
Apr 26, 2:54 PM
• !Report Abuse
Add a reply...

140 characters

Winning Will
ZLCS is on life support... I'm going down with the ship or hoping to see a nice move towards the 1.00 in 2013.
11/8/12
Reply (17)

• !Report Abuse
View all 17 replies
Winning Will: LEIGHDIST did you hold your shares? Looking a lot more promising heading into the new year!
12/2/12
• !Report Abuse
LEIGHDIST: no Will still holding on, how about you. It is looking nice, you were right.
12/3/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Gare17
If we don't hear from $ZLCS next Monday or Tuesday with Novartis renewal I think buyout rumors will start .. $NVS $MRK $PFE #Ions
Apr 26, 12:43 PM
Reply (1)

• !Report Abuse
View all 1 replies
Gare17: $ZLCS buyout or spinoff with $NVS for Chts technology
Apr 29, 4:17 PM
• !Report Abuse
Add a reply...

140 characters

Gare17
$ZLCS SEC Filings posted on company website ... buyout rumors starting
Jan 10, 4:08 AM
Reply (2)

• !Report Abuse
View all 2 replies
mr.lynch: STILL FOLLOWING $ZLCS ? IM LONG ON IT
Mar 2, 5:25 PM
• !Report Abuse
Gare17: yep long as well .. i think May - August we'll see some significant progress .. Im expecting data in September for LSR study
Apr 26, 2:54 PM
• !Report Abuse
Add a reply...

140 characters

LEIGHDIST
does anyone see ZLCS going back to 1.00 any time soon
9/27/12
Reply (16)

• !Report Abuse
View all 16 replies
mr.lynch: ZLCS opened around $11 2008, traded arord $5 3 short years ago, stock ios volatile but pipeline is undeniable, very long
Mar 2, 5:06 PM
• !Report Abuse
Ocean Man: Looks like it dropped 44% in 44 days following my recommendation to sell it.
Mar 3, 9:12 AM
• !Report Abuse
Add a reply...

140 characters

Winning Will
ZLCS is on life support... I'm going down with the ship or hoping to see a nice move towards the 1.00 in 2013.
11/8/12
Reply (17)

• !Report Abuse
View all 17 replies
Winning Will: LEIGHDIST did you hold your shares? Looking a lot more promising heading into the new year!
12/2/12
• !Report Abuse
LEIGHDIST: no Will still holding on, how about you. It is looking nice, you were right.
12/3/12
• !Report Abuse
Add a reply...

140 characters

iadops40
ZLCS reports they will discontinue further clinical development of Synavive after disapointing phase 2b data http://bit.ly/O83sQD
9/10/12
Reply (5)

• !Report Abuse
View all 5 replies
iadops40: However, for outside investors this creates a tremendous buying op. I remember early this year when PPHM went from 1 to .50...now look LOL
9/10/12
• !Report Abuse
emburns: Agree...but now look at PPHM :P
10/10/12
• !Report Abuse
Add a reply...

140 characters

Winning Will
Holding 3000 shares of ZLCS in the $.90 range. holding through 2013. Look at the technicals!.. you can say what you want about management.
10/5/12
Reply (6)

• !Report Abuse
View all 6 replies
Mafo: Yeah the cliff dive was unfortunate, but the pipeline and patience will get us back into the black!
10/5/12
• !Report Abuse
Winning Will: ouch.. honestly didnt think it would go to the $.50 range.. this one is hurting
10/10/12
• !Report Abuse
Add a reply...

140 characters

iadops40
these daily ZLCS pump articles are like clockwork, wow, almost +40% to close out August
8/31/12
Reply (1)

• !Report Abuse
View all 1 replies
emburns: The idea that SA authors can influence the market which trades a decent amount of volume is ridiculous. Probably got caught short..
9/3/12
• !Report Abuse
Add a reply...

140 characters

James Stocklasar Thomas Jr.
ZLCS on fire in premarket!
8/27/12
Reply (5)

• !Report Abuse
View all 5 replies
emburns: Entire industry is trading poorly. Entire market is trading poorly.
8/28/12
• !Report Abuse
emburns: ZLCS barely did a third of its normal ten day volume.
8/28/12
• !Report Abuse
Add a reply...

140 characters

emburns
Getting killed on ZLCS, down 10% or so... short term pain for long term gain..
8/22/12
Reply (2)

• !Report Abuse
View all 2 replies
morpin: I share your pain. Arent they supposed to be coming out with some annoucement about there progress this month?
8/22/12
• !Report Abuse
nsahbti: I guess they were expected to come out with Ph2 data mid August. Could not find anything about it or about a delay. Any word?
8/22/12
• !Report Abuse
Add a reply...

140 characters

Winning Will
ZLCS @ 1.00! Time to load up
7/17/12
Reply (3)

• !Report Abuse
View all 3 replies
Winning Will: Did you get in? Its moving
8/10/12
• !Report Abuse
Noreika: Damn, no, I hesistated and now I missed it.
8/10/12
• !Report Abuse
Add a reply...

140 characters

Winning Will
A big player out there keeps putting in hugeeeee bids for ZLCS... Get in before this one explodes!
8/1/12
Reply (1)

• !Report Abuse
View all 1 replies
wkrv: I'm in and with all the interest the chart is still flat. The player must buy then sell on .01 rise.
8/1/12
• !Report Abuse
Add a reply...

140 characters

James Stocklasar Thomas Jr.
ZLCS put front & center by Novartis VP http://seekingalpha.com/p/evw9 Zalicus up in premarket
6/4/12
Reply (3)

• !Report Abuse
View all 3 replies
x oil -field: Birds of a feather flock together.$AEZS $ZLCS he's not done yet until they,he,she, add's $AEZS to the line-up.Big winners maybe 1,000%
6/4/12
• !Report Abuse
x oil -field: But then again,they just may know something you & I do not,good day and good luck,& yes I agree, also remember both from last year.
6/4/12
• !Report Abuse
Add a reply...

140 characters

James Stocklasar Thomas Jr.
Zalicus (ZLCS) shareholders excited about this coming Tuesday. Find out why. Hint: the stock broke-out on Friday.
5/28/12
Reply (1)

• !Report Abuse
View all 1 replies
iadops40: ZLCS has a deep pipline, a good long term play
5/28/12
• !Report Abuse
Add a reply...

140 characters

James Stocklasar Thomas Jr.
ZLCS up 7% Read my report and leave a reply http://seekingalpha.com/a/d689
5/24/12
Reply (1)

• !Report Abuse
View all 1 replies
iadops40: its a buy, deep pipeline
5/24/12
• !Report Abuse
Add a reply...

140 characters

1980XLS-2.0
The ZLCS "StockLasar" is Back! LOL
3/20/12
Reply (1)

• !Report Abuse
View all 1 replies
rmw4.0: You mean captain pump and dump
3/20/12
• !Report Abuse
Add a reply...

140 characters

ZLCS Zalicus Inc.

ZLCS

Zalicus Inc.